Open AccessOverview on Gastrointestinal Stromal Tumor; A Review
Author(s) -
Hashem Bark Awadh Abood,
Amani Nasser D. Albalawi,
Haifa Obedullah AlEnazi,
Mousa Mutlaq Almuhanna,
Norah Othman Busaad,
Rafa Ghazi Ali Jarad,
Mahdi Saleh Alkhamis,
Shahad Majed Alsharif,
Mutaz Abdulrahman S. Alahdal,
Deena Ahmed S. Alqahtani,
Abdulmajeed Ramzy Alhakamy,
Sulaiman Abdullah Alraqibah
Publication year - 2021
Publication title -
journal of pharmaceutical research international
Language(s) - English
Resource type - Journals
ISSN - 2456-9119
DOI - 10.9734/jpri/2021/v33i56b33925
Subject(s) - medicine , radiology , positron emission tomography , magnetic resonance imaging , histopathology , stromal tumor , etiology , adjuvant therapy , stromal cell , pathology , chemotherapy
GISTs (gastrointestinal stromal tumours) are benign tumours that most usually affect the gastrointestinal (GI) system. GISTs can strike at any age, however they are most typically diagnosed in later life, with a median diagnostic age in the 60s. Abdominal ultrasound, CT scan, magnetic resonance imaging (MRI), and positron emission transverse tomography (PET) can all be used to detect GISTs (PET).CT enterography is the most effective method for determining the location of these tumors. Histopathology and immunochemistry are used to diagnose GISTs. Surgical excision remains the therapy of choice for gastrointestinal stromal tumours more than 2 cm that are readily resectable. Due to the possibility of resistance to standard treatment, mutational analysis should be undertaken when considering adjuvant and neoadjuvant therapy. In this review we’ll be looking at the disease etiology, epidemiology, diagnosis and management.